Fig. 2From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancera Receiver operating characteristic (ROC) curves for individual biomarkers and ProCUrE, stratifying between benign (n = 123) and CAPRA high-risk (n = 42) patients in the training cohort. PSA was not included in this figure since PSA is used to calculate CAPRA and will always have a very strong association with CAPRA high risk. b AUC (bootstrapped 1000 iterations), sensitivity, and specificity for each gene and ProCUrE. ROC **p < 0.01; ***p < 0.001Back to article page